Resistance to gefitinib in lung adenocarcinoma is caused by increased activation of the EGFR-phosphatidylinositol 4,5-bisphosphate 3-kinase (PI3K)-protein kinase B (PKB) signaling pathway by LPCAT1 [102]. The gene discussed is LPCAT1; the disease is lung adenocarcinoma.